sitagliptin + dutasteride

Sitagliptin + dutasteride is a combination of two small molecule pharmaceutical drugs, each with distinct mechanisms and indications. Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor used to improve glycemic control in adults with type 2 diabetes mellitus by increasing incretin levels, which enhances insulin secretion and decreases glucagon release in a glucose-dependent manner[2][5][6]. Dutasteride is an antiandrogenic agent that inhibits both type I and II 5α-reductase isoenzymes, leading to near-complete suppression of dihydrotestosterone (DHT) production; it is primarily indicated for the treatment of benign prostatic hyperplasia (BPH) in adult males[1]. There are no known approved fixed-dose combinations or clinical indications for the combined use of sitagliptin and dutasteride.